Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
62
TBPH Quote, Financials, Valuation and Earnings
Last price:
$20.01
Seasonality move
:
7.37%
Day range:
$19.63 - $20.31
52-week range:
$7.90 - $20.79
Dividend yield:
0%
P/E ratio:
35.57x
P/S ratio:
12.56x
P/B ratio:
4.36x
Volume:
266.5K
Avg. volume:
455.5K
1-year change:
137.09%
Market cap:
$1B
Revenue:
$64.4M
EPS (TTM):
$0.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TBPH
Theravance Biopharma, Inc.
|
$43M | -$0.05 | 129.3% | -80.69% | $26.71 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -1.23% | -39.14% | $12.3077 |
|
CORT
Corcept Therapeutics, Inc.
|
$246.1M | $0.24 | 27.74% | -71.78% | $91.00 |
|
MYO
Myomo, Inc.
|
$10.4M | -$0.09 | -13.8% | -1168.66% | $5.00 |
|
SKYE
Skye Bioscience, Inc.
|
-- | -$0.31 | -- | -22.14% | $8.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TBPH
Theravance Biopharma, Inc.
|
$20.01 | $26.71 | $1B | 35.57x | $0.00 | 0% | 12.56x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.3300 | $12.3077 | $173.2M | -- | $0.00 | 0% | 157.98x |
|
CORT
Corcept Therapeutics, Inc.
|
$34.73 | $91.00 | $3.7B | 39.68x | $0.00 | 0% | 5.60x |
|
MYO
Myomo, Inc.
|
$0.96 | $5.00 | $36.9M | -- | $0.00 | 0% | 0.95x |
|
SKYE
Skye Bioscience, Inc.
|
$1.00 | $8.25 | $32.1M | -- | $0.00 | 0% | 476.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TBPH
Theravance Biopharma, Inc.
|
16.08% | 0.446 | 6.03% | 9.30x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.281 | 0.07% | 2.85x |
|
MYO
Myomo, Inc.
|
45.68% | -2.417 | 35.87% | 1.94x |
|
SKYE
Skye Bioscience, Inc.
|
0.97% | 6.143 | 0.26% | 4.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TBPH
Theravance Biopharma, Inc.
|
$18.6M | -$6.5M | 11.74% | 14.9% | -32.29% | -$6.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
SKYE
Skye Bioscience, Inc.
|
-$178.9K | -$13.3M | -91.01% | -91.57% | -- | -$13.4M |
Theravance Biopharma, Inc. vs. Competitors
-
Which has Higher Returns TBPH or CATX?
Perspective Therapeutics, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of -12425.36%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About TBPH or CATX?
Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 33.51%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 428.23%. Given that Perspective Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TBPHTheravance Biopharma, Inc.5 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is TBPH or CATX More Risky?
Theravance Biopharma, Inc. has a beta of 0.139, which suggesting that the stock is 86.12% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock TBPH or CATX?
Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TBPH or CATX?
Theravance Biopharma, Inc. quarterly revenues are $20M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Theravance Biopharma, Inc.'s net income of $3.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 35.57x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.56x versus 157.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TBPHTheravance Biopharma, Inc.12.56x 35.57x $20M $3.6M CATXPerspective Therapeutics, Inc.157.98x -- $209K -$26M
-
Which has Higher Returns TBPH or CORT?
Corcept Therapeutics, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of 9.32%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About TBPH or CORT?
Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 33.51%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $91.00 which suggests that it could grow by 162.02%. Given that Corcept Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TBPHTheravance Biopharma, Inc.5 2 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is TBPH or CORT More Risky?
Theravance Biopharma, Inc. has a beta of 0.139, which suggesting that the stock is 86.12% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.
-
Which is a Better Dividend Stock TBPH or CORT?
Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TBPH or CORT?
Theravance Biopharma, Inc. quarterly revenues are $20M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Theravance Biopharma, Inc.'s net income of $3.6M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 35.57x while Corcept Therapeutics, Inc.'s PE ratio is 39.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.56x versus 5.60x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TBPHTheravance Biopharma, Inc.12.56x 35.57x $20M $3.6M CORTCorcept Therapeutics, Inc.5.60x 39.68x $207.6M $19.4M
-
Which has Higher Returns TBPH or MYO?
Myomo, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of -36.3%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About TBPH or MYO?
Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 33.51%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 420.83%. Given that Myomo, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Myomo, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TBPHTheravance Biopharma, Inc.5 2 0 MYOMyomo, Inc.4 0 0 -
Is TBPH or MYO More Risky?
Theravance Biopharma, Inc. has a beta of 0.139, which suggesting that the stock is 86.12% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.
-
Which is a Better Dividend Stock TBPH or MYO?
Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TBPH or MYO?
Theravance Biopharma, Inc. quarterly revenues are $20M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Theravance Biopharma, Inc.'s net income of $3.6M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 35.57x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.56x versus 0.95x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TBPHTheravance Biopharma, Inc.12.56x 35.57x $20M $3.6M MYOMyomo, Inc.0.95x -- $10.1M -$3.7M
-
Which has Higher Returns TBPH or SKYE?
Skye Bioscience, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of --. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Skye Bioscience, Inc.'s return on equity of -91.57%.
Company Gross Margin Earnings Per Share Invested Capital TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M SKYESkye Bioscience, Inc.-- -$0.32 $33.2M -
What do Analysts Say About TBPH or SKYE?
Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 33.51%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 725%. Given that Skye Bioscience, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TBPHTheravance Biopharma, Inc.5 2 0 SKYESkye Bioscience, Inc.4 2 0 -
Is TBPH or SKYE More Risky?
Theravance Biopharma, Inc. has a beta of 0.139, which suggesting that the stock is 86.12% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.680, suggesting its more volatile than the S&P 500 by 168.024%.
-
Which is a Better Dividend Stock TBPH or SKYE?
Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TBPH or SKYE?
Theravance Biopharma, Inc. quarterly revenues are $20M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Theravance Biopharma, Inc.'s net income of $3.6M is higher than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 35.57x while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.56x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TBPHTheravance Biopharma, Inc.12.56x 35.57x $20M $3.6M SKYESkye Bioscience, Inc.476.49x -- -- -$12.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
